Table 1.
Patient Characteristics
| Characteristic | Cases N = 39 (%) | Controls N = 39 (%) | p |
|---|---|---|---|
| Median age at T1 in years (25th, 75th) | 48 (41,53) | 47 (41,51) | .002 |
| Median age at T2 in years (25th, 75th) | 51 (44,56) | 50 (44,54) | .006 |
| Median time T2-T1 in months (25th,75th) | 34 (15,49) | 35 (20,49) | .52 |
| Median time event-T2 in months (25th, 75th) | 18 (5,42) | N/A | N/A |
| Male | 31 (79) | 31 (79) | Exactly matched |
| Race | |||
| White/Caucasian | 11 (28) | 6 (15) | ref |
| African American | 23 (59) | 16 (41) | .52 |
| White/Hispanic | 5 (13) | 17 (44) | .02 |
| Median CD4 (T1) (25th,75th) (cells/mm3) | 378 (229,574) | 376 (96,536) | .23 |
| Median CD4 (T2) (25th,75th) (cells/mm3) | 392 (260,589) | 435 (312,506) | .79 |
| Median HIV RNA (T1) (25th, 75th) (log10 copies/mL) | 3.94 (2.60,4.64) | 3.90 (2.60,5.46) | .38 |
| Median HIV RNA (T2) (25th, 75th) (log10 copies/mL) | 2.60 (2.60,4.36) | 2.60 (2.60,3.20) | .0001 |
| Subjects on ART (T1) | 34 (87) | 38 (97) | .22 |
| Subjects on ART (T2) | 32 (82) | 35 (90) | .52 |
| Undetectable HIV RNA (T1) | 12 (31) | 11 (28) | 1.00 |
| Undetectable HIV RNA (T2) | 22 (56) | 23 (59) | 1.00 |
| HCV Antibody + (T1) | 28 (72) | 26 (67) | .59 |
| Statin treatment (T1) | 11 (28) | 8 (21) | .62 |
| Diabetes (T1) | 13 (33) | 11 (28) | .81 |
| Hypertension (T1) | 28 (72) | 24 (62) | .45 |
| Dyslipidemia (T1) | 27 (69) | 23 (59) | .50 |
| Smoking (T1) | |||
| Current | 20 (51) | 12 (31) | .18 |
| Past | 6 (15) | 9 (23) | 1.00 |
| Never | 13 (33) | 18 (46) | ref |
| Alcohol (T1) | |||
| Current | 18 (46) | 12 (31) | .23 |
| Past | 2 (5) | 1 (3) | .85 |
| Never | 19 (49) | 26 (67) | ref |
| Illegal drug use (T1) | |||
| Current | 14 (36) | 4 (10) | .01 |
| Past | 5 (13) | 4 (10) | .42 |
| Never | 20 (51) | 31 (80) | ref |
ref, reference group for comparison.
ART, antiretroviral therapy.